Carstens C, Hostalek U
Orthopädische Universitätsklinik Heidelberg.
Klin Padiatr. 1994 Jan-Feb;206(1):22-5. doi: 10.1055/s-2008-1046575.
28 myelomeningocele patients (aged 2-30 years) with clinical symptoms of acute UTI participated in this open uncontrolled clinical trial at the Orthopedic University Hospital of Heidelberg (Dir.: Prof. Dr. H. Cotta). 4 patients were treated with 200 mg cefixime tablets bid, 24 patients received 4 mg/kg body weight cefixime suspension bid, according to age and weight of the patients. The duration of treatment was 6-10 days. Clinical and microbiological examinations were carried out before therapy as well as 1 day and 5 to 9 days after the end of treatment. The data of 25 patients could be evaluated for bacteriological and clinical efficacy. 5-9 days after treatment in 22 patients (88%) complete recovery was stated. In 3 patients a reinfection occurred. In 24 patients (96%) the baseline pathogens were eliminated under cefixime therapy. 5-9 days after the end of treatment in 3 patients reinfection was observed. Clinical side effects could be detected in 1 patient (vomiting). These results indicate that the oral cephalosporin cefixime is efficient and well tolerated in complicated UTI of myelomeningocele patients.
28例患有急性尿路感染临床症状的脊髓脊膜膨出患者（年龄2至30岁）参与了海德堡大学骨科医院（负责人：H. Cotta教授博士）开展的这项开放性非对照临床试验。根据患者年龄和体重，4例患者接受每日两次200毫克头孢克肟片治疗，24例患者接受每日两次4毫克/千克体重的头孢克肟混悬液治疗。治疗持续时间为6至10天。在治疗前以及治疗结束后1天和5至9天进行临床和微生物学检查。25例患者的数据可用于评估细菌学和临床疗效。治疗5至9天后，22例患者（88%）声明完全康复。3例患者发生再次感染。在24例患者（96%）中，头孢克肟治疗消除了基线病原体。治疗结束5至9天后，观察到3例患者再次感染。在1例患者中检测到临床副作用（呕吐）。这些结果表明，口服头孢菌素头孢克肟在脊髓脊膜膨出患者复杂尿路感染中有效且耐受性良好。
